Pop On Smiles® Leads the Way with First-Ever Probiotic Whitening Strips for a Healthier, Brighter Smile
Pop On Smiles has quickly become a popular smile solution, having delivered over 250,000 smiles and with a viral presence across Facebook, Instagram, TikTok, and YouTube.
Now you can Say Goodbye to Harsh Whitening as Pop On Continues to Redefine Oral Care Innovation with this Gentle, Science-Backed Breakthrough. This game-changing innovation is now available in Advanced Natural and Probiotic formulas, offering a gentle, peroxide-free way to brighten your smile, without harsh chemicals, pain, or slipping strips.
"We didn't just want to whiten teeth—we wanted to reinvent what a whitening strip could be," said the Pop On Product Innovation Team. "By blending powerful plant-based ingredients with oral probiotics, we're giving people a reason to feel good about every step of their smile care. This isn't your average whitening strip."
Why These Whitening Strips Are a Game-Changer
First Whitening Strips with ProbioticsLactobacillus, a clinically studied probiotic, is included to help balance oral bacteria and support fresh breath, healthy gums, and fewer bad bacteria. It's an innovation no other whitening strip offers.
Peroxide-Free & Sensitivity SafeForget the burning and zinging that comes with traditional peroxide-based strips. Pop On uses natural enzymes like Papain (from papaya) and Bromelain (from pineapple) to gently dissolve surface stains—leaving your teeth brighter without irritation.
Powered by Nature + ScienceEach strip is packed with a thoughtful blend of effective, natural ingredients:
Coconut Oil: Soothes gums and helps reduce harmful bacteria
Xylitol: A natural sweetener that supports enamel and fights cavities
Hydroxyapatite: A tooth-rebuilding mineral that strengthens enamel while whitening
Lemon Peel & Peppermint Oils: Offer a refreshing flavor and gentle stain-lifting power
Lactobacillus Probiotics: Promote a balanced oral microbiome for fresh breath and healthy gums
No-Slip TechnologyUnlike other strips that slide around or fall off, Pop On's advanced base formulation ensures the strips stay firmly in place for a mess-free, stay-put experience—so you can whiten confidently whether you're working, running errands, or relaxing at home.
Designed for Everyday Life
30-minute treatments—quick and easy for everyday use
No residue—just peel, apply, and toss
Fresh mint or coconut flavor—both flavors available
Safe for daily use—thanks to enamel-protecting and non-irritating ingredients
Three convenient sizes: Available in packs of 7, 14, or 21 treatments
Available Now on Amazon and on PopOn's website
Customers can shop the Advanced or Probiotic versions directly on Amazon https://poponsmiles.com
There, customers can also discover Pop On's flagship 100% custom made Pop On Veneers, and other smile essential products like Pop On Fresh Foam, Pop On Clean Tablets and more.
About Pop On Smiles®
Pop On Smiles® is on a mission to make stunning smiles affordable, accessible, and achievable—without invasive procedures, harsh chemicals, or high costs. With over 250,000 smiles delivered and counting, Pop On continues to lead the future of smile care with comfort, confidence, and innovation at its core.
Due to Popular demand, Pop On has extended their support hours by phone (347) 929-3358, text 76766 (POPON) and email team@poponveneers.com Monday-Friday 9:00am est -10:00pm est.
Customers can also visit Pop On at their flagship location in midtown Manhattan 237 W 37th St. New York, NY 10018
Media Contact:
pr@poponveneers.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/pop-on-smiles-leads-the-way-with-first-ever-probiotic-whitening-strips-for-a-healthier-brighter-smile-302516470.html
SOURCE Pop On Smiles
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Doctors Say Injecting Botox Here Can Make You Look Fresher And More Awake. This Is How To Tell If It's Right For You.
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." These days, it seems like there's nothing Botox can't do—or, rather, nowhere it can't be injected). Whether it's the jaw, the traps, or the neck, the beloved injectable is being used for way more than just smoothing wrinkles. At the top of the list? Lifting your brows. Yes, the social media hype is real: A few needle pokes can in fact leave you with more elevated arches. 'Patients, of all ages, are asking for the Botox brow lift by name,' says Jessica Weniger, the lead aesthetic medicine physician assistant at the Med Spa at Northwestern in Chicago. Why the hype, and why now? Meet the experts: Jessica Weniger, is the lead aesthetic medicine physician assistant at the Med Spa at Northwestern in Chicago. Joshua Korman, MD, is a board-certified plastic surgeon in California. Teresa Song, MD, a board-certified dermatologist in New York City. There are a few factors at play. There's the social media effect, of course. The content around the #botoxbrowlift is plentiful and spikes people's interest, says Weniger, who notes that the same thing happened with lip flips. Hand-in-hand with the TikTok and Instagram of it all is the fact that more and more young people are using Botox. 'Twentysomethings are curious and thinking about what they can do to prevent the signs of aging,' says Joshua Korman, MD, a board-certified plastic surgeon in California. 'The brows, which naturally drop as you age, are a big component of that.' Similarly, he says there's an increased focus on brows in general, noting that he's also seen an uptick in surgical brow lifts. And finally, there's the fact that a Botox brow lift strikes the perfect balance between delivering legitimate results while still looking totally natural. You can leave the rest of your face alone and just do a Botox brow lift to create an open-eyed, naturally youthful appearance, says Teresa Song, MD, a board-certified dermatologist in New York City. So, is it all great as it sounds? Here, the lowdown on how Botox can raise your brows up. What exactly is a Botox brow lift? A quick refresher: Botox is the brand name of botulinum toxin A, an injectable neuromodulator that works by relaxing the muscles that cause dynamic wrinkles (those lines that form when your facial muscles move). Botox is just one of many brand names: Dysport, Juveau, and Xeomin are other popular options, and all of them can be used for brow lifting purposes, says Dr. Song. 'Botox just has the name recognition, so it gets used to describe the entire category, much like calling a tissue a Kleenex,' adds Weniger. During a Botox brow lift, the neuromodulator is injected into the orbicularis oculi muscle, which is situated in a circular formation surrounding the eye. This muscle pulls the eyebrow down, so when you relax it, the brow is lifted and the eye appears more open, Weniger explains. Squint and shut one eye tight: 'You can actually see where the muscle pulls downward,' says Weniger. 'It's above where any crow's feet would be. This very upper portion of the muscle is what we're targeting when we inject for a Botox brow lift.' Two other muscles—the corrugators, which kick in when you frown, and the frontalis muscle, the big one across the front of your forehead—can also be strategically injected during a Botox brow lift. Injecting here helps to also raise the middle part of the eyebrow, which often makes for the most natural end result, says Dr. Song. Raising just the tail of the eyebrow can sometimes create an strange, cartoon villain-esque appearance, adds Dr. Korman. Who is a good candidate for a Botox brow lift? Anyone wants to lift their brows and make their eyes look a little more open can totally try this, assures Dr. Korman. That's in stark contrast to a surgical lift, which he reserves for older patients only (this in order to minimize the likelihood of needing future surgeries as they continue to age). A Botox brow lift is also a good way to correct any minor asymmetry, which is very common, notes Weniger. And arches aside, this procedure might actually help address some upper eyelid sagging, too. 'It won't remove excess skin the way a surgical upper blepharoplasty will, but injecting in this area can provide a bit of lift for lids that are hooded or droopy,' she says. Dr. Song agrees: 'Pull upwards on the outside edge of your brow. If this raises your upper eyelid, you'll likely see the same effect with a Botox brow lift.' What to expect during a Botox brow lift. Your injector will talk through your concerns and goals and take before photos. Some may choose to mark up the areas they'll be treating, but everyone should have you make a few facial expressions. 'If they don't ask you to animate, that's an absolute red flag,' Weinger cautions. 'They need to be able to see what the muscle is doing and how it's behaving. Everyone's anatomy is a little different and injection points aren't a one-size-fits-all.' If you just want the outside part of your eyebrow lifted, expect about one to four tiny injections per side, Weinger says. If you also want to raise the middle part, it will be double that, adds Dr. Song. An important FYI: While you can absolutely opt for just a Botox brow lift, it's more often than not combined with treating the crow's feet and/or forehead. But because of how the muscles all interact, it can be tricky to smooth out horizontal forehead lines and lift the brows. If you're concerned about both, talk to your injector about how to achieve the best possible results in all areas, advises Weniger. Happily, no pain equals a lot of gain. Weniger says her patients are consistently surprised by how fast, easy, and nearly painless a Botox brow lift is. (A tiny needle means the pokes feel like a tiny pinch, nothing more.) Still, if your pain tolerance is non-existent, ask your injector to ice the spots they'll be injecting for a few minutes beforehand. This works wonders to numb the skin so you really won't feel anything, Weniger says. How long does a Botox brow lift last? 'The bad thing about Botox is it's not permanent; the good thing about Botox is it's not permanent,' says Dr. Korman. Point being, if you love the results, you'll have to repeat the process every three to four months. Not thrilled? No harm, no foul. Just keep in mind that all injectable neuromodulators work on a bell curve. 'The full results kick in at the two week mark, then gradually come back down to baseline over the course of three to four months,' Weniger explains. To that point, if you want to boost your brows before a big event, make sure you schedule your appointment a few weeks out in order to see the best effect, Dr. Song advises. How much does a Botox brow lift cost? This depends largely on your provider and where you live. 'Some places charge by the unit, other areas charge by the area treated,' says Weniger. When it's just a Botox brow lift, the area is small and you typically only need 10 to 20 units she says, citing anywhere from $150 to $400 as an average. What are the risks of a Botox brow lift? Bruising is a risk with any injections, though can be more likely around the eyes where the skin is so thin, Weniger explains. The good news: Because the needles are so small, the bruises will be too. Much more serious (albeit less likely) is the risk of ptosis, or unwanted eyelid drooping. It's not a super-high risk, because you really need to inject the muscle much deeper than you should be, but it is possible, says Dr. Song. The best way to minimize the likelihood of this happening? Always see an experienced, licensed, injector. Make no mistake about it: A Botox brow lift isn't a direct, one-to-one substitute for its surgical counterpart. You won't get the same amount of lift, excess skin can't be removed, and it really is best for lifting just the tail of the brow, says Dr. Korman. And, of course, you'll have to schedule regular appointments in order to maintain the results. Still, for those who don't want to go under the knife, 'This is about as good as it gets,' says Dr. Song. 'The brows set the tone for the face. You can modify them with something that has a long and well-studied history, and not look completely overdone.' So, as long as you keep your expectations realistic and prep your calendar (and wallet) for several treatments per year, you may quickly find yourself a member of the Botox brow lift fan club. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
Business Wire
2 hours ago
- Business Wire
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook
LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook Share Second Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 37% to $31.1 million, with Tru Niagen® sales reaching $22.7 million, growing 22%. Niagen® ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade. Gross margin increased 480 basis points to 65.0%. Sales and marketing expense as a percentage of net sales was 26.4%, an improvement of 420 basis points. Net income of $3.6 million or $0.05 earnings per share, up from breakeven in prior year quarter. Adjusted EBITDA, a non-GAAP measure, increased 221% to $5.0 million. Total cash provided by operations of $9.1 million during the six months ended June 30, 2025, ending the quarter with $60.5 million in cash. Increased full year 2025 outlook: Net sales growth expected between 22%–27% (previously between 20%–25%), reflecting continued execution and leadership in the expanding NAD+ market. Recent Operational Highlights On June 9, 2025, the Company announced the publication of the first peer-reviewed clinical study of Niagen® in individuals with Werner syndrome, a rare premature aging disorder in Aging Cell. The 52-week randomized trial showed Niagen® significantly increased NAD+ levels and improved clinical markers of cardiovascular and skin health, supporting further investigation in rare, age-related diseases. On July 8, 2025, the Company entered into a worldwide exclusive license agreement with Haukeland University Hospital in Bergen, Norway, securing proprietary rights to develop and commercialize its patented nicotinamide riboside (Niagen®) as a potential pharmaceutical therapy for Parkinson's disease (PD). This agreement includes access to extensive clinical data, including from the Phase III NOPARK trial, and supports the Company's broader efforts to advance regulated therapeutic applications for neurodegenerative conditions. During June 2025, patient dosing the Phase III NOPARK trial was completed, the largest and most comprehensive clinical study of NAD+ augmentation in persons with early PD to date. NOPARK is a randomized, double-blind, placebo-controlled phase III clinical trial featuring 400 individuals with early-stage PD across 12 sites in Norway. Randomized to receive either 500 mg of nicotinamide riboside (Niagen) twice daily or placebo for 52 weeks, participants had follow-up assessments at five time points in a one-year period. The primary endpoint is the MDS-UPDRS total score, a gold standard measure of PD progression. Data analysis is underway and the data from this phase 3 trial is expected to be published in 2026. On July 14, 2025, the Company announced the launch of Tru Niagen® as an exclusive in-room amenity, and introduced Niagen IV at The Spa by Equinox Hotel New York through NutriDrip, marking Niagen Bioscience's entry into luxury hospitality. While featured at a single location, Equinox's sole hotel property, the launch aligns with a premium, health-conscious demographic and serves as a potential model for broader hospitality partnerships. As of August 2025, Niagen Plus products, including Niagen IV and injectables, are available in over 800 leading wellness clinics in the U.S., up from more than 475 clinics in December 2024. This growth reflects accelerating adoption by clinics and rising demand for clinically administered NAD+ solutions. Niagen Plus products are compounded and distributed through U.S. FDA-registered 503B outsourcing facilities and offered exclusively by prescription through participating wellness clinics. 'We delivered an excellent second quarter, with $31.1 million in net sales, up 37% year-over-year, and $3.6 million in net income,' said Niagen Bioscience CEO Rob Fried. 'As the pioneers of this blossoming NAD+ market, we continue to invest in the future while maintaining our focus on profitable growth." Results of operations for the three months ended June 30, 2025 compared to the prior year quarter Net Sales for Niagen Bioscience increased 37%, or $8.4 million, to $31.1 million. The growth in net sales was driven by combined growth in Tru Niagen® sales and Niagen® ingredient sales, including strong e-commerce channel performance, stronger demand for food-grade Niagen® and the ramp-up of pharmaceutical-grade Niagen® sales, which were not sold in the prior year quarter. Gross Margin improved 480 basis points to 65.0% primarily due to changes in product mix, business mix, the use of lower-cost inventory purchases, and improvements in labor and overhead utilization rates with higher sales. These gross margin improvements may not be indicative of future performance and certain drivers, such as lower-cost inventory purchases, are likely to be temporary in nature. Gross margins are expected to normalize in future periods. Operating Expense increased 22%, or $3.1 million, to $17.0 million reflecting investments for business growth and brand awareness. Selling and marketing expense increased $1.2 million, and improved 420 basis points as a percentage of net sales to 26.4% of net sales, reflecting improved sales efficiency and disciplined investment. The increase in expenses primarily reflects higher investments to support brand growth in our consumer products segment. General and administrative expense increased $1.6 million, or 28%, primarily driven by higher employee-related expenses, share-based compensation, and professional and consulting fees. Research and development expenses increased $0.3 million due to higher professional and consulting fees, as well as higher employee-related expenses. Net Income was $3.6 million, or $0.05 per share, compared to approximately break-even net loss and loss per share for the second quarter of 2024. Adjusted EBITDA, a non-GAAP measure, was $5.0 million, up from $1.6 million for the second quarter of 2024. See 'Reconciliation of Non-GAAP Financial Measures' for a reconciliation of non-GAAP Adjusted EBITDA to net income (loss), the most directly comparable GAAP measure. Cash Flows from Operating Activities had a net cash inflow of $9.1 million for the six months ended June 30, 2025 compared to approximately break-even cash flows in the prior year. The approximately $9.1 million increase in cash provided by operating activities was primarily driven by improvements in net income (loss), relatively higher collections on trade receivables, and a relative increase in accounts payable. These increases were partially offset by a decrease in credit loss expense due to a recovery of previously written-off amounts and higher inventory purchases associated with scaling our inventory reserves. 2025 Full Year Outlook Looking forward, for the full year, the Company is revising its revenue growth expectation from 20% to 25% year-over-year to 22% to 27%. This outlook reflects anticipated continued expansion of the Company's e-commerce business as well as growth through new and established partnerships. Gross margin is expected to improve slightly year-over-year compared to 61.8% in 2024, driven by ongoing supply chain optimization efforts, cost savings initiatives, and overall business scale. The Company is also updating its outlook for sales and marketing expenses. These costs are now expected to increase in absolute dollars compared to $29.5 million in 2024, but decrease as a percentage of net sales compared to 29.6% of net sales in 2024. This compares to the prior guidance of an increase in absolute dollars with a stable percentage of net sales year over year. The updated projection reflects the Company's continued strategic investments to enhance and strengthen brand awareness and support its various business channels while enhancing efficiencies. The Company remains committed to maintaining steady investments in research and development throughout 2025, with spending expected to align closely with fiscal year 2024 levels ($6.0 million), to continue driving future innovation. General and administrative expenses are expected to increase by approximately $7.0 to $8.0 million, primarily due to share-based compensation and investments in business growth and the absence of a $3.5 million royalty expense reversal that occurred in 2024. Investor Conference Call A live webcast will be held Wednesday, August 6, 2025 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss Niagen Bioscience's second-quarter financial results and provide a general business update. To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investors Relations section of Niagen Bioscience's website at The toll-free dial-in information for this call is 1-888-596-4144 with Conference ID: 8584242. The webcast will be recorded, and will be available for replay via the website from 7:30 p.m. Eastern time on August 6, 2025 through 11:59 p.m. Eastern time on August 13, 2025. The replay of the call can also be accessed by dialing 1-800-770-2030, using the Replay ID: 8584242. Important Note on Forward Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as 'expects,' 'anticipates,' 'intends' 'estimates,' 'plans,' 'potential,' 'possible,' 'probable,' 'believes' 'seeks,' 'may,' 'will,' 'should,' 'could,' 'predicts,' 'projects,' 'continue,' 'would' or the negative of such terms or other similar expressions. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the quotation from Niagen Bioscience's Chief Executive Officer, statements related to the Company's 2025 financial outlook including but not limited to revenue growth, gross margin, expenses, investment plans, and the statements regarding Niagen Plus. Risks that contribute to the uncertain nature of the forward-looking statements include: inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; including unanticipated developments in and risks related to the Company's ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company's ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company's ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company's ability to maintain and enforce the Company's existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities; economic and market instability, including as a result of tariffs or trade conflicts; and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q as filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. About Niagen Bioscience, Inc.: Niagen Bioscience is a global bioscience company dedicated to healthy aging. The Niagen Bioscience team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors. Niagen Bioscience is the innovator behind the NAD+ precursor nicotinamide riboside chloride ('NRC' commonly referred to as 'NR'), commercialized as the flagship ingredient Niagen®, available in both food and pharmaceutical grades. Nicotinamide riboside chloride and other NAD+ precursors are protected by Niagen Bioscience's patent portfolio. The Company delivers Niagen® as the sole or principal dietary ingredient in its consumer product line Tru Niagen® available at and through partnerships with global retailers and distributors. The Company also develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen® and pharmaceutical-grade Niagen®, and supplies these ingredients as raw materials to the manufacturers of consumer products and U.S. FDA-registered 503B outsourcing facilities, respectively. The Company further offers natural product fine chemicals, known as phytochemicals, and related research and development services. Follow us on X (formerly Twitter) @NiagenBio and Instagram @TruNiagen and @NiagenPlus and subscribe to our latest news via our website accessible at to which Niagen Bioscience regularly posts copies of its press releases as well as additional updates and financial information about the Company. Niagen Bioscience, Inc. and Subsidiaries Unaudited Condensed Consolidated Balance Sheets (In thousands except par values, unless otherwise indicated) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents, including restricted cash of $152 for both periods presented $ 60,474 $ 44,660 Trade receivables, net of allowances of $199 and $95, respectively 9,656 7,768 Inventories 14,406 9,192 Prepaid expenses and other assets 2,143 2,482 Total current assets 86,679 64,102 Leasehold improvements and equipment, net 1,632 1,719 Intangible assets, net 284 359 Right-of-use assets 2,525 1,730 Other long-term assets 405 368 Total assets $ 91,525 $ 68,278 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 13,680 $ 8,526 Accrued expenses 7,381 7,817 Current maturities of operating lease obligations 957 982 Current maturities of finance lease obligations 6 12 Customer deposits 303 611 Total current liabilities 22,327 17,948 Deferred revenue 2,674 2,579 Operating lease obligations, less current maturities 2,329 1,657 Total stockholders' equity 64,195 46,094 Total liabilities and stockholders' equity $ 91,525 $ 68,278 Expand Niagen Bioscience, Inc. and Subsidiaries Unaudited Condensed Consolidated Statements of Cash Flows Six Months Ended June 30, (In thousands) 2025 2024 Net cash provided by / (used in): Operating activities $ 9,133 $ 31 Investing activities (167 ) (53 ) Financing activities 6,848 582 Net increase in cash and cash equivalents 15,814 560 Cash and cash equivalents beginning of period 44,660 27,325 Cash and cash equivalents at end of period $ 60,474 $ 27,885 Expand Niagen Bioscience, Inc. and Subsidiaries Unaudited Reconciliation of Non-GAAP Financial Measures Reconciliation of Net Income (Loss) to Adjusted EBITDA (In thousands) Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Net income (loss), as reported $ 3,609 $ 5,063 $ 7,179 $ 1,878 $ (15 ) Adjustments: Interest income, net (552 ) (459 ) (373 ) (276 ) (241 ) Provision for income taxes 128 168 305 — — Depreciation 158 158 151 164 170 Amortization of intangibles 38 37 38 38 37 Noncash lease expense 159 173 169 164 163 Share-based compensation 1,488 1,075 752 735 1,185 Severance and restructuring 21 4 (4 ) 185 276 Reversal of previously accrued royalties and license maintenance fees (1) — — (3,521 ) — — Recovery of credit losses related to legal settlement (2) — (1,325 ) (1,325 ) — — Adjusted EBITDA $ 5,049 $ 4,894 $ 3,371 $ 2,888 $ 1,575 Expand (1) The reversal of previously accrued royalties and license maintenance fees related to a supplemental agreement with Dartmouth, which waived certain obligations under the exclusive license agreements. (2) The recovery of credit losses relates to the 2024 legal settlement with Elysium Health, LLC, paid in two installments, reversing a bad debt write-off from 2019. Expand Non-GAAP Financial Information: To supplement Niagen Bioscience's unaudited financial data presented in accordance with generally accepted accounting principles (GAAP), the Company has presented Adjusted EBITDA, a non-GAAP financial measure. Niagen Bioscience believes the presentation of this non-GAAP financial measure provides important supplemental information to management and investors and enhances the overall understanding of the Company's historical and current financial operating performance. The Company believes disclosure of the non-GAAP financial measure has substance because the excluded expenses are infrequent in nature, are variable in nature or do not represent current cash expenditures. Further, such non-GAAP financial measure is among the indicators the Company uses as a basis for evaluating the Company's financial performance as well as for planning and forecasting purposes. Accordingly, disclosure of this non-GAAP financial measure provides investors with the same information that management uses to understand the Company's economic performance year-over-year. Adjusted EBITDA is defined as net income (loss) before (a) interest, (b) provision for income taxes, (c) depreciation, (d) amortization, (e) non-cash share-based compensation costs, (f) severance and restructuring expense and (g) other infrequent items, including the reversal of previously accrued royalties and license maintenance fees, and the recovery of previously recognized credit losses from a legal settlement. While Niagen Bioscience believes that this non-GAAP financial measure provides useful supplemental information to investors, there are limitations associated with the use of such measure. This measure is not prepared in accordance with GAAP and may not be directly comparable to similarly titled measures of other companies due to potential differences in the method of calculation. Management compensates for these limitations by relying primarily on the Company's GAAP results and by using Adjusted EBITDA only supplementally and by reviewing the reconciliation of the non-GAAP financial measure to its most comparable GAAP financial measure. Non-GAAP financial measures are not prepared in accordance with, or an alternative for, generally accepted accounting principles in the United States. The Company's non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP.
CNET
2 hours ago
- CNET
Jury Decides Meta Stole Data from Users of Period-Tracking App: What to Do If You're Worried
A California jury ruled Wednesday that Meta broke state privacy laws by collecting data from the popular Flo app, including private health data and pregnancy goals. The case claimed that, among other actions, Meta used the data to create targeted advertising content. As Meta claims it will fight the verdict, the court continues to decide specific financial damages – and the plaintiffs have asked for billions. A representative for Meta did not immediately respond to a request for comment. The consolidated Flo lawsuit dates to 2021, when users of the Flo app accused major tech companies of harvesting their data and actions on the period-tracking app, which included personal profiles about their menstrual cycles, sexual activity, pregnancy history and a variety of other personal health information. Originally, the lawsuit included the creators of the Flo app, Google, and the analytics company Flurry, as well as Meta. All the other companies settled, most recently Flo Health in late July, leaving only Meta to continue with the trial, which has now concluded. The primary accusation of the lawsuit revolves around the software development kit from Meta--then known as Facebook--that Flo Health incorporated into its app. This kit allowed Flo to send different types of user data to Facebook, including buttons users clicked and data they shared with the app. The lawsuit claimed this violated the California Invasion of Privacy Act. The jury agreed that Meta had intentionally eavesdropped on the plaintiffs when they had a reasonable expectation of privacy, and did not have consent to eavesdrop or record data in this way. Meta, on the other hand, denies the jury's verdict is correct. According to reports, the company will appeal the decision and has stated, "The plaintiffs' claims against Meta are simply false. User privacy is important to Meta, which is why we do not want health or other sensitive information and why our terms prohibit developers from sending any." Should you be worried about using the Flo app? Tracking periods on an app may not be the most efficient option, anyway. EKIN KIZILKAYA via Getty The good news is that when Flo settled in 2021, part of the bargain was to arrange an independent privacy review and require explicit consent when sharing data. So if you've been using Flo for the past several years, your data has probably been safe from this particular problem. But issues with data harvesting and sharing like this raise broader questions about how safe it is to use health apps if you're concerned with privacy. Fortunately, there are plenty of alternatives. CNET has guides on how wearables like the Oura ring can help track period data without the same problematic privacy past. We've also covered ways to track menstrual cycles without relying on an app at all, so you have plenty of alternatives.
